Results 171 to 180 of about 8,893 (235)

GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study. [PDF]

Diabetes Obes Metab
Tesfaye H, Paik JM, Wexler DJ, Hathaway JT, Yu EW, Freedman A, Rizzo JF, Patorno E.   +7 more
europepmc   +1 more source

Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis. [PDF]

JHEP Rep
Li L, Mao X, Lee CH, Wai Lui DT, Wan-Hin Hui R, Mak LY, Yuen MF, Cheung KS, Seto WK.   +8 more
europepmc   +1 more source

Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes. [PDF]

Clin Kidney J
Kanbay M, Al-Shiab R, Shah E, Ozbek L, Guldan M, Ortiz A, Fouque D.   +6 more
europepmc   +1 more source

Comparative Effectiveness of SGLT2i and GLP-1RA on Blood Pressure in Hypertensive Patients with Type 2 Diabetes: A Saudi Multicenter Retrospective Study. [PDF]

J Clin Med
Alshehri G, Alrashidi R, Alhaqbani R, Almeshari R, Bin Sheraim N, Alharbi A, Al Yami MS, Alanazi A, Alsalamah N, Alrossies A.   +9 more
europepmc   +1 more source

Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure. [PDF]

Biomedicines
Wang W, Green D, Ibrahim R, Abdelnabi M, Pham HN, Forst B, Allam M, Sarkis P, Bcharah G, Farina J, Ayoub C, Sorajja D, Arsanjani R.   +12 more
europepmc   +1 more source

Effects of GLP-1RA Treatment on Long-Term Post-PCI Prognosis in T2DM Patients: A Propensity Score Matching Study. [PDF]

Diabetes Metab Syndr Obes
Fang B, Liu F, Luo J, Song N, Liu C, Ji W, An X, Xie Q, Yang Y, Li X.   +9 more
europepmc   +1 more source

Identifying High-Risk Obese Individuals Without Diabetes for GLP-1RA Therapy Using Coronary CTA. [PDF]

JACC Adv
Blair CV, Huck D, Besser SA, Cardoso R, Shiyovich A, Berman AN, Biery DW, Weber BN, Petranovic M, Nasir K, Hedgire S, Plutzky J, Cannon C, Di Carli MF, Ghoshhajra BB, Trinquart L, Blankstein R.   +16 more
europepmc   +1 more source

Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods. [PDF]

Cardiovasc Diabetol
Morieri ML, Longato E, Sciannameo V, Donatiello E, Berchialla P, Avogaro A, Consoli A, Fadini GP.   +7 more
europepmc   +1 more source

Missed Doses, Missed Opportunities: Readmission Due to GLP-1RA Interruption Inspires Algorithms to Improve Reinitiation of Therapy at Discharge. [PDF]

Hosp Pharm
Michelet A, Mowla M, Amo-Brown BA, Rodriguez N, Cavaretta M.   +4 more
europepmc   +1 more source

Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study. [PDF]

Sci Rep
Zeng H, Hu J, Zhuo Y, Wang M, Gao L, Tang Z, Zhang J, Yin P, Gu J, Wang C.   +9 more
europepmc   +1 more source